Pulmonx Corporation
LUNG Healthcare Medical Devices
Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024. In the quarter to June 2026, revenue fell 4.62%, EPS grew 36.8%, free cash flow fell 31.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow LUNG
Pulmonx Corporation (LUNG) EV/Sales
As of 16 October 2026, Pulmonx Corporation (LUNG) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from 0.2× (August 2025) to 44.8× (April 2021); the current reading is higher than 17% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.6× | (73.74%) |
| FY2024 | 2.4× | (59.04%) |
| FY2023 | 5.9× | 104.32% |
| FY2022 | 2.9× | (86.09%) |
| FY2021 | 20.6× | 37.64% |
| FY2020 | 15.0× | 318.23% |
| FY2019 | 3.6× | 0.00% |
| FY2018 | 3.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.4× | 25.64% |
| Mar 2026 | 0.3× | (47.06%) |
| Dec 2025 | 0.6× | 116.76% |
| Sep 2025 | 0.3× | (54.11%) |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OM Outset Medical, Inc. compare | 0.2× |
| LUNG Pulmonx Corporation | 0.7× |
| ZOMDF Zomedica Corp. compare | 0.9× |
| LNSR LENSAR, Inc. compare | 1.1× |
| ECOR electroCore, Inc. compare | 1.9× |
| APYX Apyx Medical Corporation compare | 2.2× |
| HYPR Hyperfine, Inc. compare | 2.6× |
| LUCD Lucid Diagnostics Inc. compare | 14.3× |
| SERA Sera Prognostics, Inc. compare | 822× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)